These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34169833)

  • 1. A real-world, single-center experience of the utilization of hepatitis C-viremic kidneys for hepatitis C-negative recipients.
    Daloul R; Anthony M; Washburn K; Singh P; Pesavento T
    Clin Nephrol; 2021 Oct; 96(4):216-225. PubMed ID: 34169833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.
    Kapila N; Menon KVN; Al-Khalloufi K; Vanatta JM; Murgas C; Reino D; Ebaid S; Shaw JJ; Agrawal N; Rhazouani S; Navas V; Sheffield C; Rahman AU; Castillo M; Lindenmeyer CC; Miller C; Quintini C; Zervos XB
    Hepatology; 2020 Jul; 72(1):32-41. PubMed ID: 31659775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of direct acting antiviral therapies in hepatitis C virus-negative liver transplant recipients of hepatitis C-viremic donors.
    Snyder HS; Wiegel JJ; Khalil K; Summers BB; Tan T; Jonchhe S; Kaiser TE
    Pharmacotherapy; 2022 Dec; 42(12):905-920. PubMed ID: 36373198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care.
    Bohorquez H; Bugeaud E; Bzowej N; Scheuermann J; Hand J; Bruce D; Carmody I; Cohen A; Joshi S; Seal J; Sonnier D; Therapondos G; Girgrah N; Anders S; Loss GE
    Liver Transpl; 2021 Apr; 27(4):548-557. PubMed ID: 33098277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors.
    Smith DE; Chen S; Fargnoli A; Lewis T; Galloway AC; Kon ZN; Moazami N
    Semin Thorac Cardiovasc Surg; 2021; 33(2):407-415. PubMed ID: 32621962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
    Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report.
    Said A; Weiss M; Varhelyi A; Farago R; Ballweg C; Rice J; Agarwal P; Fernandez L; Foley D
    Transpl Infect Dis; 2021 Apr; 23(2):e13466. PubMed ID: 32931616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era.
    Kapila N; Al-Khalloufi K; Bejarano PA; Vanatta JM; Zervos XB
    Am J Transplant; 2020 Feb; 20(2):600-605. PubMed ID: 31448549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
    Reyentovich A; Gidea CG; Smith D; Lonze B; Kon Z; Fargnoli A; Pavone J; Rao S; Saraon T; Lewis T; Qian Y; Jacobson I; Moazami N
    Clin Transplant; 2020 Sep; 34(9):e13989. PubMed ID: 32441413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report.
    Cuvelier S; Van Caeseele P; Kadatz M; Peterson K; Sun S; Dodd N; Werestiuk K; Koulack J; Nickerson P; Ho J
    Can J Kidney Health Dis; 2021; 8():20543581211033496. PubMed ID: 34367648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.
    Molnar MZ; Azhar A; Tsujita M; Talwar M; Balaraman V; Bhalla A; Podila PSB; Kothadia J; Agbim UA; Maliakkal B; Satapathy SK; Kovesdy CP; Nair S; Eason JD
    Am J Kidney Dis; 2021 May; 77(5):739-747.e1. PubMed ID: 33333148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience.
    Jandovitz N; Nair V; Grodstein E; Molmenti E; Fahmy A; Abate M; Bhaskaran M; Teperman L
    Transpl Infect Dis; 2021 Jun; 23(3):e13540. PubMed ID: 33259125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
    Czarnecka P; Czarnecka K; Tronina O; Baczkowska T; Durlik M
    Ren Fail; 2022 Dec; 44(1):434-449. PubMed ID: 35260039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: A systematic review with meta-analysis.
    Villegas-Galaviz J; Anderson E; Guglin M
    J Heart Lung Transplant; 2022 Apr; 41(4):538-549. PubMed ID: 35153130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.